VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | JAKARTA 1 & 2: response rapidity & durability

Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the rapidity and durability of response, in the JAKARTA1 (NCT01437787) and JAKARTA2 (NCT01523171) studies evaluating fedratinib in patients with intermediate or high-risk myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter